December 2015

New Product - Imbruvica

Imbruvica (ibrutinib) is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK). Preclinical studies have shown that ibrutinib inhibits B cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro. Imbruvica is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) who have received at least one prior therapy or as first line in patients with CLL with 17p deletion, and in patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Use of preparations containing St. John’s wort is contraindicated in patients treated with Imbruvica. Imbruvica is available as 140 mg tablets in packs of 90’s and 120’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au